Friday, August 04, 2023
ABVC BioPharma has received approval from the Science Park Administration in Taiwan to establish a pilot Good Manufacturing Practise (GMP) facility. This facility will be dedicated to producing Vitargus®, an innovative product used in retinal detachment surgery.
In addition to production, ABVC BioPharma will focus on refining their manufacturing processes for optimal efficiency. The joint effort between ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation focuses on the enhancement of manufacturing processes for Vitargus®.
Vitargus®, a cutting-edge Vitreous Substitute, represents the first biodegradable hydrogel product intended for use in retinal detachment surgery. Having successfully concluded a feasibility study in Australia, Vitargus® received approval from the Australian Therapeutic Goods Administration (TGA) to proceed with the next phase of trials.
The focus on enhancing the facility's infrastructure is to yield substantial reductions in ongoing trial expenses, optimise production processes, kerbing costs linked to outsourcing to external Contract Research Organisations (CROs), and ensuring heightened operational efficiency.
